Results 271 to 280 of about 35,569 (305)

The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists

Current Medicinal Chemistry
Abstract: Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short
Haowen, Fang, Bing, Niu, Qin, Chen
openaire   +2 more sources

[Glucagon-like peptide-1 receptor agonists].

Nihon rinsho. Japanese journal of clinical medicine, 2015
Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Youth Obesity

JAMA Pediatrics
This Viewpoint discusses the use of glucagon-like peptide-1 receptor agonist treatments for weight management in youth.
Emma K, Edmondson, Rachana D, Shah, Emily F, Gregory   +2 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists in Gynecologic Surgery

Obstetrics & Gynecology
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly expanded beyond their initial role in diabetes management to become prominent agents for weight loss and metabolic optimization. A growing number of patients receiving these therapies are presenting for gynecologic surgery. This narrative review summarizes current evidence on GLP-1 RAs,
Richard, Hsu, Esther, Han, Sarah, Swartz, Michelle, Pacis   +3 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency

Molecular Pharmaceutics, 2019
Type 2 diabetes mellitus (T2DM) is increasing in global prevalence and is associated with serious health problems (e.g., cardiovascular disease). Various treatment options are available for T2DM, including the incretin hormone glucagon-like peptide-1 (GLP-1).
Seyed Ebrahim Alavi, Peter J. Cabot, Peter M. Moyle   +2 more
openaire   +5 more sources

Glucagon-like peptide-1 receptor agonists

2016
Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
openaire   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?

JAMA Internal Medicine, 2022
Shanzay, Haider, Kasia J, Lipska
openaire   +2 more sources

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

Diabetes, Obesity and Metabolism, 2023
Christoph Kapitza, Michael Desch, Anita M Hennige   +2 more
exaly  

Glucagon-Like Peptide-1 Receptor Agonists and Cancer

JAMA Oncology
Mahyar, Etminan, Connor, Frey, Mohammad A, Mansournia   +2 more
openaire   +4 more sources

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide

Diabetes, Obesity and Metabolism, 2021
Michele Schiavon, Roberto Visentin, Claudio Cobelli   +2 more
exaly